282,718例住院患者中脑出血与2019冠状病毒病的队列研究
该研究基于Cerner去标识化COVID-19数据集(62家医疗机构),纳入85,645例COVID-19患者和197,073例无COVID-19患者,比较脑出血风险及结局。多变量模型校正混杂因素后,COVID-19患者脑出血风险更低(OR 0.5;95%CI 0.5-0.6;P<.0001)。合并脑出血的COVID-19患者肺炎、急性肾损伤、急性心肌梗死、脓毒症和呼吸衰竭比例均显著更高,院内死亡率显著更高(40.3% vs 19.0%;P<.0001)。结论提示COVID-19不增加脑出血发生率,但合并脑出血时死亡风险更高,可能与合并症和不良事件更多相关。
要点
- 在85,645例COVID-19患者中脑出血发生率为0.2%(154例),无COVID-19的197,073例中为0.3%(667例)。
- 多变量校正后COVID-19患者脑出血风险更低(OR 0.5;95%CI 0.5-0.6;P<.0001),校正因素包括性别、年龄分层、种族/民族、高血压、糖尿病等。
- 合并脑出血的COVID-19患者院内死亡率40.3%,显著高于无COVID-19的脑出血患者19.0%(P<.0001)。
- 合并脑出血的COVID-19患者肺炎(58.4% vs 22.5%)、急性肾损伤(48.7% vs 31.0%)、脓毒症(41.6% vs 22.5%)、呼吸衰竭(61.7% vs 42.3%)比例显著更高。
- 急性心肌梗死比例在合并脑出血的COVID-19患者中为11%,无COVID-19者为6.4%(P=.048)。
适用人群与场景
- 来自62家医疗机构的住院或急诊就诊患者,出院诊断编码提示疑似或暴露于COVID-19或确诊COVID-19者纳入COVID-19组,无COVID-19者为对照组。
诊断标准与关键阈值
- 原文未提及脑出血的诊断标准或评分界值。
- 原文未提及COVID-19的诊断标准或严重程度分层标准。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征。
研究设计与关键结果
- 研究类型为回顾性队列分析,数据来自Cerner去标识化COVID-19数据集,覆盖62家医疗机构,共282,718例住院患者(85,645例COVID-19,197,073例无COVID-19)。
- 主要终点为脑出血发生率:COVID-19组0.2%(154例),无COVID-19组0.3%(667例);多变量校正后OR 0.5(95%CI 0.5-0.6;P<.0001)。
- 关键次要终点:合并脑出血的COVID-19患者院内死亡率40.3%,显著高于无COVID-19的脑出血患者19.0%(P<.0001)。
- 其他不良事件:肺炎58.4% vs 22.5%、急性肾损伤48.7% vs 31.0%、急性心肌梗死11% vs 6.4%、脓毒症41.6% vs 22.5%、呼吸衰竭61.7% vs 42.3%,合并脑出血的COVID-19组均显著更高(P值分别<.0001、<.0001、=.048、<.0001、<.0001)。
- 原文未提及不良事件的具体定义或严重程度分级。
证据类型、等级与局限
- 证据类型为回顾性队列研究,基于去标识化行政数据库,非随机对照试验。
- 局限性:回顾性设计、依赖出院诊断编码可能错分、无法排除未测量的混杂因素、数据来自特定数据库(62家医疗机构)可能影响外推性。
对床旁实践的改变
- 该研究不提示COVID-19患者脑出血风险高于无COVID-19者,临床不应仅因COVID-19诊断而过度担心脑出血风险。
- 对于合并脑出血的COVID-19患者,应警惕更高的院内死亡风险(40.3% vs 19.0%)及肺炎、急性肾损伤、脓毒症、呼吸衰竭等不良事件的高发生率。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To identify whether the risk of intracerebral hemorrhage is higher in patients with coronavirus disease 2019 (COVID-19), we compared the risk factors, comorbidities, and outcomes in patients intracerebral hemorrhage and COVID-19 and those without COVID-19.
METHODS: We analyzed the data from the Cerner deidentified COVID-19 data set derived from 62 health care facilities. The data set included patients with an emergency department or inpatient encounter with discharge diagnoses codes that could be associated with suspicion of or exposure to COVID-19 or confirmed COVID-19.
RESULTS: There were a total of 154 (0.2%) and 667 (0.3%) patients with intracerebral hemorrhage among 85,645 patients with COVID-19 and 197,073 patients without COVID-19, respectively. In the multivariate model, there was a lower risk of intracerebral hemorrhage in patients with COVID-19 (odds ratio 0.5; 95% confidence interval 0.5-0.6; p < .0001) after adjustment for sex, age strata, race/ethnicity, hypertension, diabetes mellitus, nicotine dependence/tobacco use, hyperlipidemia, atrial fibrillation, congestive heart failure, long-term anticoagulant use, and alcohol abuse. The proportions of patients who developed pneumonia (58.4% versus 22.5%; p < .0001), acute kidney injury (48.7% versus 31.0%; p < .0001), acute myocardial infarction (11% versus 6.4%; p = .048), sepsis (41.6% versus 22.5%; p < .0001), and respiratory failure (61.7% versus 42.3%; p < .0001) were significantly higher among patients with intracerebral hemorrhage and COVID-19 compared with those without COVID-19. The in-hospital mortality among patients with intracerebral hemorrhage and COVID-19 was significantly higher compared with that among those without COVID-19 (40.3% versus 19.0%; p < .0001).
CONCLUSIONS: Our analysis does not suggest that rates of intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage and COVID-19 compared with those without COVID-19 is likely mediated by higher frequency of comorbidities and adverse in-hospital events.
参考来源
- Qureshi AI, Baskett WI, Huang W, et al. Intracerebral Hemorrhage and Coronavirus Disease 2019 in a Cohort of 282,718 Hospitalized Patients. Neurocrit Care. 2021. PMID: 34231186. doi:10.1007/s12028-021-01297-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。